par INVENTIVA (EPA:IVA)
Inventiva Announces Temporary Trading Halt of its Ordinary Shares on Euronext Paris
PRESS RELEASE
Inventiva Announces Temporary Trading Halt of its Ordinary Shares on Euronext Paris
Daix (France), New York City (New York, United States), June 2, 2026 – Inventiva (Euronext Paris and NASDAQ: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral therapies for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”), today announces that the listing of its ordinary shares on the regulated market of Euronext Paris will be temporarily halted, at the Company's request, from the opening of the market at 9:00 a.m. CEST.
This suspension comes ahead of a proposed financing transaction, details of which will be announced in a new communication of the Company.
This suspension will be effective until a new communication is released by the Company. Trading on Euronext Paris is expected to resume today, June 2, 2026, at approximately 3:30 p.m. CEST, which is the earliest time ADSs are expected to begin trading on the Nasdaq Global Market (9:30 a.m. ET), under the ticker symbol "IVA".
About Inventiva
Inventiva is a clinical-stage biopharmaceutical company focused on the research and development of an orally administered small molecule for the treatment of patients with MASH. The Company is currently evaluating lanifibranor, a novel pan-PPAR agonist, in the NATiV3 pivotal Phase 3 clinical trial for the treatment of adult patients with MASH, a common and progressive chronic liver disease.
Inventiva is a public company listed on compartment B of the regulated market of Euronext Paris (ticker: IVA, ISIN: FR0013233012) and on the Nasdaq Global Market in the United States (ticker: IVA). https://www.inventivapharma.com
Contacts
Media Relations
Pascaline Clerc: media@inventivapharma.com
Mark Corbae: inventivapr@icrhealthcare.com
Investor Relations
David Nikodem: IR@inventivapharma.com
Patricia L. Bank: patti.bank@icrhealthcare.com